FDA Allows Capricor to Resubmit Duchenne Drug Data
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Capricor's deramiocel received a negative advisory committee vote on its secondary outcome related to heart function stabilization in boys with Duchenne muscular dystrophy, particularly in those with initially stable hearts.
- FDA allowed Capricor to submit additional upper limb performance data as the primary outcome after weighing the time required for new trials against potential loss of patient function.
- Mindy Leffler, whose son has Duchenne and has been on deramiocel for five years, developed the Duchenne Video Assessment used in Capricor’s Phase 3 study and consults on its data.
- Deramiocel showed clearer efficacy in a subpopulation of patients with existing heart dysfunction, but results were noisier in the broader group, complicating regulatory interpretation.
- Duchenne muscular dystrophy trials involve high-stakes design decisions—such as outcome selection and inclusion criteria—that balance statistical power with real-world applicability and enrollment feasibility.
Why it matters: Patients and families gain from FDA’s willingness to accept reanalyzed data without requiring lengthy new trials, preserving critical treatment time. For biotechs developing rare disease therapies, this sets a precedent that adaptive analysis can coexist with scientific rigor when patient outcomes are at stake.
Ask SkimNews
